The group actively explores innovative analytical approaches, including causal inference, Bayesian methods, real-world data analytics, artificial intelligence, and machine learning, to enhance trial design, optimize operational efficiency, and generate deeper insights from complex clinical and translational datasets. As an integral part of the Translational Medicine Unit, the EGDS group applies rigorous statistical principles to support evidence generation and data-driven decision-making across the drug development lifecycle, from first-in-human studies to pivotal registration trials.